+

PE20080262A1 - Anticuerpo humanizado contra interleuquina-18 - Google Patents

Anticuerpo humanizado contra interleuquina-18

Info

Publication number
PE20080262A1
PE20080262A1 PE2007000638A PE2007000638A PE20080262A1 PE 20080262 A1 PE20080262 A1 PE 20080262A1 PE 2007000638 A PE2007000638 A PE 2007000638A PE 2007000638 A PE2007000638 A PE 2007000638A PE 20080262 A1 PE20080262 A1 PE 20080262A1
Authority
PE
Peru
Prior art keywords
seq
interleuquin
humanized antibody
antibody against
sec
Prior art date
Application number
PE2007000638A
Other languages
English (en)
Inventor
Jonathan Henry Ellis
Volker Germaschewski
Paul Andrew Hamblin
Ian Kirby
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38476914&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080262(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0610438A external-priority patent/GB0610438D0/en
Priority claimed from GB0611046A external-priority patent/GB0611046D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20080262A1 publication Critical patent/PE20080262A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Analytical Chemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)

Abstract

SE REFIERE A UN ANTICUERPO HUMANIZADO CONTRA INTERLEUQUINA-18 QUE TIENE LAS SIGUIENTES CDR: CDRH1:SEC.ID.N:1; CDRH2:SEC.ID.N:2; CDRH3:SEC.ID.N:3; CDRL1:SEC.ID.N:4; CDRL2:SEC.ID.N:5; CDRL6:SEC.ID.N:6, EN LAS QUE EL RESTO DE LA POSICION 71 DE LA CADENA LIGERA ESTA SUSTITUIDO POR UN AMINOACIDO SELECCIONADO DE TIROSINA, ADEMAS DE TENER UNA AFINIDAD DE UNION (KD) DE 90 pM O SUPERIOR CON RESPECTO A IL-18 HUMANA CUANDO SE MIDE RESONANCIA DE PLASMON SUPERFICIAL (POR EJEMPLO BIACORE T100) A 37C. REFERIDA TAMBIEN A UNA COMPSICION FARMACEUTICA UTIL EN EL TRATAMIENTO DE ENFERMEDADES AUTOINMUNITARIAS TALES COMO ESCLEROSIS MULTIPLE, ARTRITIS REUMATOIDE, DIBETES TIPO 1, ENFERMEDAD INFLAMATORIA DEL INTESTINO (EII) Y SORIASIS
PE2007000638A 2006-05-25 2007-05-23 Anticuerpo humanizado contra interleuquina-18 PE20080262A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0610438A GB0610438D0 (en) 2006-05-25 2006-05-25 Immunoglobulins
GB0611046A GB0611046D0 (en) 2006-06-05 2006-06-05 Immunoglobulins

Publications (1)

Publication Number Publication Date
PE20080262A1 true PE20080262A1 (es) 2008-04-30

Family

ID=38476914

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000638A PE20080262A1 (es) 2006-05-25 2007-05-23 Anticuerpo humanizado contra interleuquina-18

Country Status (22)

Country Link
US (5) US8133978B2 (es)
EP (1) EP2027157B1 (es)
JP (1) JP5420399B2 (es)
KR (1) KR101416078B1 (es)
AR (1) AR061115A1 (es)
AU (1) AU2007267213B2 (es)
BR (1) BRPI0711908B8 (es)
CA (1) CA2652733C (es)
CR (1) CR10468A (es)
EA (1) EA017303B1 (es)
ES (1) ES2514495T3 (es)
IL (1) IL194995A0 (es)
MA (1) MA30486B1 (es)
MX (1) MX2008014842A (es)
MY (1) MY157173A (es)
NO (1) NO341921B1 (es)
NZ (1) NZ572565A (es)
PE (1) PE20080262A1 (es)
SG (1) SG172625A1 (es)
TW (1) TWI422387B (es)
WO (1) WO2007137984A2 (es)
ZA (1) ZA200809662B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
EP3056568B1 (en) 2006-03-31 2021-09-15 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
WO2007137984A2 (en) * 2006-05-25 2007-12-06 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
ES2566957T3 (es) 2007-09-26 2016-04-18 Chugai Seiyaku Kabushiki Kaisha Región constante de anticuerpo modificado
MX369784B (es) 2007-09-26 2019-11-21 Chugai Pharmaceutical Co Ltd Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
SG10201608379YA (en) 2008-04-11 2016-11-29 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
EP2326315A1 (en) * 2008-08-18 2011-06-01 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists
CN102132143B (zh) * 2008-08-27 2013-11-27 弗·哈夫曼-拉罗切有限公司 筛选高亲和力抗体的方法
TWI440469B (zh) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
WO2010040736A2 (en) * 2008-10-07 2010-04-15 Ablynx Nv Amino acid sequences directed against il18 and/or the il-18 receptor and polypeptides comprising the same for the treatment of diseases and/or disorders associated with il-18 mediated signaling
WO2010107110A1 (ja) 2009-03-19 2010-09-23 中外製薬株式会社 抗体定常領域改変体
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
WO2011023623A1 (en) 2009-08-25 2011-03-03 F. Hoffmann-La Roche Ag Velocity factor
EA201290630A1 (ru) * 2010-02-09 2013-03-29 Глаксо Груп Лимитед Лечение расстройства обмена веществ
RU2012147249A (ru) 2010-04-07 2014-05-20 Эббви Инк. TNF-α- СВЯЗЫВАЮЩИЕ БЕЛКИ
EA027256B1 (ru) 2010-11-23 2017-07-31 Глаксо Груп Лимитед АНТИГЕНСВЯЗЫВАЮЩИЕ БЕЛКИ, СВЯЗЫВАЮЩИЕСЯ С ОНКОСТАТИНОМ М ЧЕЛОВЕКА (hOSM)
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
US20130149308A1 (en) * 2011-08-12 2013-06-13 Genentech, Inc. Antibodies to il-1beta and il-18, for treatment of disease
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
ES2742413T3 (es) 2012-11-21 2020-02-14 Km Biologics Co Ltd Nuevo anticuerpo humano contra IL-18
ES2869396T3 (es) * 2013-05-15 2021-10-25 Medimmune Ltd Purificación de polipéptidos producidos de manera recombinante
US10782290B2 (en) 2013-06-11 2020-09-22 National Center Of Neurology And Psychiatry Method for predicting post-therapy prognosis of relapsing-remitting multiple sclerosis (RRMS) patient, and method for determining applicability of novel therapy
AU2016224409B2 (en) 2015-02-27 2021-01-28 Chugai Seiyaku Kabushiki Kaisha Composition for treating IL-6-related diseases
US10697883B2 (en) 2015-05-19 2020-06-30 National Center Of Neurology And Psychiatry Method for determining application of therapy to multiple sclerosis (MS) patient
WO2017076805A1 (en) * 2015-11-02 2017-05-11 Glaxosmithkline Intellectual Property Development Limited Use of an inhibitor of il18 for treatment of acute kidney injury
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD OF PREDICTION AND EVALUATION OF THERAPEUTIC EFFECT IN DISEASES RELATING TO IL-6 AND NEUTROPHILS
JP7235249B2 (ja) 2017-10-20 2023-03-08 学校法人兵庫医科大学 抗ｉｌ－６受容体抗体を含有する術後の癒着を抑制するための医薬組成物
WO2021206766A1 (en) 2020-04-09 2021-10-14 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
US11324750B2 (en) 2020-04-09 2022-05-10 Children's Hospital Medical Center Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection
EP3892280A3 (en) 2020-04-09 2022-01-12 Children's Hospital Medical Center Sars-cov-2 infection biomarkers and uses thereof
EP4371573A1 (en) 2021-07-13 2024-05-22 National University Corporation Tokai National Higher Education and Research System Medicinal composition for treating inflammatory bowel disease
US20240425560A1 (en) * 2021-09-29 2024-12-26 Chimera Bioengineering, Inc. IL-18 Variants and Uses Thereof
WO2024261470A1 (en) 2023-06-20 2024-12-26 Apollo Ap43 Limited Anti-il-18 antibody therapy for treating atopic dermatitis

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
GB9109645D0 (en) * 1991-05-03 1991-06-26 Celltech Ltd Recombinant antibodies
RU2139351C1 (ru) * 1991-04-25 1999-10-10 Чугаи Сейяку Кабусики Кайся Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности
ATE188708T1 (de) 1991-08-21 2000-01-15 Novartis Ag Antikörperderivate
GB9125979D0 (en) 1991-12-06 1992-02-05 Wellcome Found Antibody
GB9412230D0 (en) 1994-06-17 1994-08-10 Celltech Ltd Interleukin-5 specific recombiant antibodies
US6048972A (en) * 1994-07-13 2000-04-11 Chugai Pharmaceutical Co., Ltd. Recombinant materials for producing humanized anti-IL-8 antibodies
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
JP2952750B2 (ja) 1995-02-23 1999-09-27 株式会社林原生物化学研究所 モノクローナル抗体
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
DK1787999T3 (da) * 1997-04-07 2010-11-15 Genentech Inc Anti-VEGF-antistoffer
IL121860A0 (en) 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
AR022952A1 (es) 1999-03-19 2002-09-04 Smithkline Beecham Corp ANTICUERPO MONOCLONAL DE ROEDOR ESPECIFICAMENTE NEUTRALIZANTE PARA LA INTERLEUQUINA-18 HUMANA , UN FRAGMENTO FAB NEUTRALIZANTE o FRAGMENTO F(AB')2, UNA REGION DE COMPLEMENTARIEDAD DE CADENA LIGERA DE INMONOGLOBULINA(CDR), UNA MOLECULA DE ACIDO NUCLEICO, COMPOSICION FARMACEUTICA QUE LO COMPRENDE, EL
CN102504024A (zh) * 2000-02-10 2012-06-20 雅培制药有限公司 结合人白介素-18的抗体及制备和使用方法
TR200202030T2 (tr) 2000-02-21 2003-01-21 Applied Research Systems Ars Holding N.V. IL-18 inhibitörlerinin kullanımı.
US20020025317A1 (en) 2000-07-20 2002-02-28 Schering Ag Bispecific monoclonal antibodies to IL-12 and IL-18
MXPA03003144A (es) * 2000-10-13 2004-12-06 Biogen Inc Anticuerpos humanizados anti-lt-??-r.
WO2002032374A2 (en) 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
JPWO2002066063A1 (ja) 2001-02-23 2004-06-17 星野　友昭 代謝性骨疾患治療剤
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
UA78516C2 (en) 2001-08-10 2007-04-10 Applied Research Systems Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity
WO2004097019A1 (ja) 2003-04-30 2004-11-11 Japan Science And Technology Agency ヒト抗ヒトインターロイキン－１８抗体およびその断片、並びにそれらの利用方法
US20050100965A1 (en) 2003-11-12 2005-05-12 Tariq Ghayur IL-18 binding proteins
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
SI1730191T1 (sl) * 2004-03-30 2011-11-30 Glaxo Group Ltd Imunoglobulin-vezavni hOSM
GB0425556D0 (en) 2004-11-19 2004-12-22 Glaxo Group Ltd Novel compounds
GB0600488D0 (en) 2006-01-11 2006-02-22 Glaxo Group Ltd Immunoglobulins
AU2007217563A1 (en) 2006-02-22 2007-08-30 University Of Zurich Methods for treating autoimmune or demyelinating diseases
WO2007137984A2 (en) * 2006-05-25 2007-12-06 Glaxo Group Limited Modified humanised anti-interleukin-18 antibodies
EP2326315A1 (en) 2008-08-18 2011-06-01 Glaxo Group Limited Treatment of an autoimmune disease using il-18 antagonists

Also Published As

Publication number Publication date
NO341921B1 (no) 2018-02-19
AU2007267213A1 (en) 2007-12-06
US8133978B2 (en) 2012-03-13
EA017303B1 (ru) 2012-11-30
US20140105894A1 (en) 2014-04-17
KR20090023625A (ko) 2009-03-05
EP2027157B1 (en) 2014-08-06
AU2007267213B2 (en) 2012-03-29
US20190031753A1 (en) 2019-01-31
KR101416078B1 (ko) 2014-07-07
CA2652733A1 (en) 2007-12-06
US20070292432A1 (en) 2007-12-20
CA2652733C (en) 2016-06-21
TWI422387B (zh) 2014-01-11
US9499617B2 (en) 2016-11-22
MY157173A (en) 2016-05-13
US10703814B2 (en) 2020-07-07
NO20084650L (no) 2008-12-19
BRPI0711908B1 (pt) 2020-08-04
JP5420399B2 (ja) 2014-02-19
US20120100137A1 (en) 2012-04-26
BRPI0711908B8 (pt) 2021-05-25
SG172625A1 (en) 2011-07-28
TW200808350A (en) 2008-02-16
US20170029497A1 (en) 2017-02-02
EP2027157A2 (en) 2009-02-25
ZA200809662B (en) 2014-05-28
CR10468A (es) 2009-01-09
AR061115A1 (es) 2008-08-06
IL194995A0 (en) 2011-08-01
MA30486B1 (fr) 2009-06-01
MX2008014842A (es) 2009-02-17
BRPI0711908A2 (pt) 2012-01-03
US8637018B2 (en) 2014-01-28
ES2514495T3 (es) 2014-10-28
WO2007137984A3 (en) 2008-01-24
NZ572565A (en) 2011-04-29
EA200802182A1 (ru) 2009-06-30
JP2009537608A (ja) 2009-10-29
WO2007137984A2 (en) 2007-12-06

Similar Documents

Publication Publication Date Title
PE20080262A1 (es) Anticuerpo humanizado contra interleuquina-18
PE20170687A1 (es) Proteinas de enlace a cd127
CO2020014727A2 (es) Anticuerpo anti proteína reguladora de señales alfa sirpαlfa
AR081556A1 (es) Proteinas de union al antigeno humanizadas
PE20080181A1 (es) Anticuerpos que se unen al peptido beta-amiloide en el tratamiento de alzheimer
AR068723A1 (es) Proteina que se une a antigenos que se une a il-23 humana y sus usos
AR071891A1 (es) Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano)
HRP20201432T1 (hr) Il-17a sredstvo za vezivanje i njegove uporabe
PE20142243A1 (es) Anticuerpos que se unen a ox40 y sus usos
AR080698A1 (es) Anticuerpo o fragmento del mismo que especificamente enlaza la variante de csf -1r humano, composicion farmaceutica que lo comprende, su uso para la manufactura de un medicamento util para el tratamiento de cancer y metodo para determinar si un sujeto es candidato para tratamiento de cancer basado e
CL2013003140A1 (es) Un anticuerpo monoclonal humano aislado o fragmento de union a antigeno del mismo que se une a masp-2 humana; molecula de acido nucleico, casette de expresion, celula que la expresa, metodo de produccion, composicion que la contiene, articulo que lo contiene.
HRP20170882T1 (hr) Humani antigen-vezujući proteini koji se vežu za beta-klotho, fgf receptore i njihove komplekse
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
JP2013517277A5 (es)
PE20142242A1 (es) Anticuerpos humanos anti-cd27, metodos, y usos
JP2015522252A5 (es)
ES2571129T3 (es) Anticuerpos anti-CTLA4 humanizados
PE20120429A1 (es) Proteinas de enlace de miostatina
PE20200011A1 (es) ANTICUERPOS ANTI-PEPTIDO BETA AMILOIDE N3pGlu Y SUS USOS
ME00519B (me) Antitijela visokog afiniteta prema humanom il-6 receptoru
RU2588467C3 (ru) Стабильные и растворимые антитела, ингибирующие vegf
JP2015508762A5 (es)
NZ610153A (en) Novel anti-dr5 antibody
MX2014001371A (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
PE20140133A1 (es) Nuevas proteinas de union a antigenos

Legal Events

Date Code Title Description
FG Grant, registration
FD Application declared void or lapsed
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载